Caligor Enhances Operational and Commercial Leadership to Meet Growing Global Demand for Its Clinical Trial Supply Services

On Mar 1, 2017

Following a record year for its clinical trial supply and global access services in 2016, Caligor Opco LLC, which has a facility in Secaucus, further enhanced its operational and commercial leadership teams, appointing David Edwards as its new Chief Executive Officer. Tammy Bishop will assume the new role of Chief Commercial Officer and continue to be a member of the Board of Directors.

Mr. Edwards will be based at Caligor’s European headquarters in Dartford, UK, which includes the Company’s new state-of-the-art storage and distribution facility. Mr. Edwards has broad management experience with leading healthcare companies and a successful track record of growing businesses in the U.S., Europe and Asia. Most recently he was the East Asia Vice President for Alcon, a Novartis company and a global leader in eye care. Mr. Edwards also served as President of the Asia-Pacific region at Bausch & Lomb and spent more than a decade in executive management positions at Johnson & Johnson. He was President of Johnson & Johnson’s diabetes business unit in Europe, the Middle East and Africa, led the Johnson & Johnson Vision Care business in the Asia-Pacific region and headed Johnson & Johnson’s Consumer Nutritionals business in Europe.

“David is a seasoned executive who brings a strong pedigree and proven expertise across multiple areas of the life sciences industry,” said Ron Nayot, a Managing Director of Caligor’s parent company, Diversis Capital LLC. “Over a career that spans more than 25 years, David has helped to drive operational excellence at some of the industry’s premier companies. His skill in developing new products, building international brands and guiding organizational growth will provide a solid foundation for our future success.”

“Caligor plays a mission-critical role in reducing risks within the global clinical trial supply chain and assuring the safe, ethical and efficient distribution of comparator drugs on behalf of our clients,” Mr. Edwards said. “Through its investments in people, infrastructure and technology, Diversis is demonstrating its commitment to our business. I’m excited to join such a dynamic, rapidly growing organization. I look forward to applying my experience and leadership to continue to expand our strategic service offerings and our international presence.”

Ms. Bishop joined Caligor as Managing Director in 2010 and served as CEO following the Company’s acquisition by Diversis in 2016, a transaction that she helped lead. Ms. Bishop has more than 25 years of commercial marketing experience in the pharmaceutical industry, having previously served in senior business development and marketing roles at clinical trial supply firms Pharmarama and IDIS Pharmaceuticals.

“Tammy has built great relationships with our clients because she understands the importance of delivering accurate, timely, cost-effective services that enable pharma and biopharma companies to focus on what they do best – improving patient outcomes,” Mr. Nayot said. “As Chief Commercial Officer, she will be Caligor’s primary client interface, ensuring that all functions within the organization are aligned to meet our commercial objectives.

“The appointments of the CEO and CCO for Caligor reflect our investment commitment to this high growth business. The depth of experience across our executive team will enable us to continue to exceed customer expectations globally, and build an industry leading set of integrated strategic clinical trial and global access services,” Mr. Nayot said.

Related Articles: